Holen Sie sich die Stockscreener-App
57.88
0.04%
-0.005
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$57.88
Offen:
$58.16
24-Stunden-Volumen:
1.37M
Relative Volume:
0.13
Marktkapitalisierung:
$117.83B
Einnahmen:
$47.44B
Nettoeinkommen (Verlust:
$-7.26B
KGV:
14.69
EPS:
3.94
Netto-Cashflow:
$13.80B
1W Leistung:
-1.10%
1M Leistung:
+11.01%
6M Leistung:
+36.88%
1J Leistung:
+19.34%
1-Tages-Spanne:
$57.47
$58.22
1-Wochen-Bereich:
$55.82
$58.83
52-Wochen-Spanne:
$39.35
$61.08
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Vergleichen Sie BMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| BMY | 57.85 | 117.83B | 47.44B | -7.26B | 13.80B | 3.94 |
| LLY | 739.15 | 693.54B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 102.13 | 465.74B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 153.52 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 169.00 | 294.70B | 55.53B | 5.12B | 15.62B | 3.65 |
| MRK | 97.75 | 248.54B | 63.17B | 12.15B | 14.84B | 1.80 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
John G Ullman & Associates Inc. Decreases Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Is Bristol Myers Squibb Stock a Buy? - The Motley Fool
Primecap Management Co. CA Has $1.21 Billion Stock Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Commerce Bank Sells 30,241 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
77,494 Shares in Bristol-Myers Squibb (NYSE:BMY) Acquired by B. Metzler seel. Sohn & Co. Holding AG - MarketBeat
Vital Signs: Merck maps Keytruda's next act in the injectables marketplace - FirstWord Pharma
Psoriasis Market is expected to rise at a significant CAGR, DelveInsight | Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb - Barchart
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Premier Fund Managers Ltd Takes Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
CAMZYOS™ Honoured with the Prix Galien Canada Innovative Product Award - cnhinews.com
GLP-1 Analogues Market Outlook: Rapid Growth at 21.3% CAGR to Surpass USD 322.85 Billion by 2034 | PMR - GlobeNewswire Inc.
BRISTOL-MYERS SQUIBB CANADA WINS THE 2024 PRIX GALIEN INNOVATIVE PRODUCT AWARD - Barchart
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
J&J, Protagonist's oral psoriasis prospect scores in phase 3 pair, readying case against BMS' Sotyktu - Fierce Biotech
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by PNC Financial Services Group Inc. - MarketBeat
BMS CFO backs “resilient” pharma industry amid RFK’s impending governance - Pharmaceutical Technology
OneAscent Financial Services LLC Purchases Shares of 8,855 Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Why Bristol Myers Squibb is a Top 25 Dividend Giant (BMY) - Nasdaq
Bristol Myers to Present 90+ Studies at ASH, Including 5-Year Breyanzi Data | BMY Stock News - StockTitan
Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Natixis Advisors LLC - MarketBeat
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases - Benzinga
Is Bristol-Myers Squibb Company (BMY) the Best Immunotherapy Stock to Buy Now? - Insider Monkey
EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer - Pharmaceutical Technology
Bristol-Myers Squibb: Buy This Bargain Stock Before It's Gone (NYSE:BMY) - Seeking Alpha
Swiss National Bank Boosts Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Kinsale Capital Group Inc. Purchases 18,163 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Mizuho Markets Americas LLC Lowers Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Kentucky Retirement Systems Lowers Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Bristol-Myers Squibb (NYSE:BMY) Trading Down 3%Here's Why - MarketBeat
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer - BioSpace
Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue - Benzinga
EU regulators endorse meds from BMS, J&J, Eisai and more—plus a clutch of biosims - FiercePharma
Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Sheaff Brock Investment Advisors LLC - MarketBeat
BMYBristol-Myers Squibb Co. Latest Stock News & Market Updates - StockTitan
Cornercap Investment Counsel Inc. Reduces Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Now Covered by Analysts at Wolfe Research - MarketBeat
Celgene Shareholders Hit BMS with Fresh Lawsuit for Allegedly Dodging CVR Payments - BioSpace
Bristol Myers' Cancer Drug Repotrectinib Gains Key EU Panel Backing for Lung Cancer | BMY Stock News - StockTitan
The Bristol Myers Squibb Foundation - Bristol Myers Squibb
Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug - MSN
Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug - Reuters
Justice on the Move: The Impact of Bristol-Myers Squibb on FLSA Forum-Shopping - The National Law Review
9,269 Shares in Bristol-Myers Squibb (NYSE:BMY) Bought by Sargent Investment Group LLC - MarketBeat
Bristol-Myers Squibb Company's (NYSE:BMY) high institutional ownership speaks for itself as stock continues to impress, up 5.7% over last week - Yahoo Finance
Bristol-Myers Squibb (NYSE:BMY) Stake Lessened by KBC Group NV - MarketBeat
Plato Investment Management Ltd Purchases 13,447 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Clinical trials & studies - Bristol Myers Squibb
Bristol Myers Squibb showcases cardiovascular portfolio at AHA Scientific Sessions 2024 - Indian Pharma Post
ICICI Prudential Asset Management Co Ltd Sells 38,500 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.22%
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):